Please assess the completion status of the following clinical trial:

Trial Title: Add-on to Thiazolidinedione (TZD) Failures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, ≥ 18 years old, with type 2 diabetes and with inadequate glycemic control~* All subjects must have central laboratory pre-randomization A1C ≥ 7.0 and ≤ 10.5%~* C-peptide ≥ 1.0 ng/mL (0.34 nmol/L)~* Body Mass Index ≤ 45.0 kg/m²~Exclusion Criteria:~* AST and /or ALT \> 2.5 times the upper limit of normal~* Serum total bilirubin \> 2 mg/dL (34.2 µmol/L)~* Creatinine kinase \> 3.0 times the upper limit of normal~* Symptoms of severely uncontrolled diabetes~* Serum creatinine ≥ 2.0 mg/dL~* Calculated Cr-Clearance \< 50 ml/min (calculated by Cockroft-Gault formula)~* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: EXPERIMENTAL): None
- Arm 3 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).